Lenvatinib mesilate (lenvatinib) is an oral multiple-receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of Vascular Endothelial Growth Factor Receptor (VEGFR) 1-3, Fibroblast Growth Factor Receptor (FGFR) 1-4, Platelet-Derived Growth Factor Receptor (PDGFR) α, KIT, and RET.
Background: Despite the crucial role of integrin receptors in cancer pathogenesis and massive efforts towards establishing clinically relevant drugs, to the present no effective integrin antagonist for the treatment of malignant diseases has been introduced into the clinic.
26S proteasome is an intracellular; ATP dependent enzymatic complex degrades ubiquitin-tagged proteins and maintains cellular homeostasis. The orderly degraded proteins including cyclins, caspases, Bcl-xL, p53, cell adhesion molecules are involved in cell-cycle progression, tumor suppression, DNA replication, inflammation, and apoptosis. So, proteasome inhibition is a target therapy for cancer to promote cell cycle arrest or apoptosis.
Primary oral leiomyosarcomas are exceptionally rare lesions often associated with poor prognosis. We report a case of leiomyosarcoma arising in the anterior mandibular gingiva, which is a non-prevalent site of occurrence. Clinically, the tumor was far from being firm and solid as it is usually described in the literature. Light microscopy failed to confirm the true nature of the lesion on the biopsy specimen.
The financial crisis has a dramatic impact on social life, since reduced or even non-existent incomes affect people's well-being and push big parts of the population to poverty.
Eribulin sensitivity was examined in a panel of twenty-five human cancer cell lines representing a variety of tumor types, with a preponderance of breast and lung cancer cell lines. As expected, the cell lines vary in sensitivity to eribulin at clinically relevant concentrations.
Thyroid cancer (TC) is the most common endocrine malignancy and its incidence hasbeen increasing sharply since the mid-1990s [1]. TC is a general term that comprises two main groups of neoplasias, depending on the cell type affected by the malignant transformation.
Non-Hodgkin's lymphomas (NHLs) are the second fastest growing cancer in terms of incidence and deaths in the United States and Europe. NHLs are a heterogeneous cancer group including several haematological neoplasias with different degree of aggressiveness. In spite of the progresses, conventional therapies do not ensure long-term survival [1].
Abstract: Cisplatin is one of the most widely applied antineoplastic agents used to treat different types of solid tumours. However, its use is limited by serious side- effects including nephrotoxicity. Cisplatin accumulates in proximal tubule and forms nephrotoxins that causes proximal cell injury and thereby leads to nephrotoxicity. Cisplatin enters these proximal cells by organic transporter molecules (OCT). Genetic polymorphism of these molecules and other membrane transport proteins that regulate cisplatin accumulation may influence cisplatin- related nephrotoxic outcome.
About Journal 
Aims & Scope 
Submit Manuscript